0001589150 false --09-30 2022 Q3 0001589150 2021-10-01 2022-06-30 0001589150 2022-07-17 0001589150 2022-06-30 0001589150 2021-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2022-06-30 0001589150 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesMMember 2022-06-30 0001589150 RGBP:SeriesMMember 2021-09-30 0001589150 RGBP:SeriesNCMember 2022-06-30 0001589150 RGBP:SeriesNCMember 2021-09-30 0001589150 2022-04-01 2022-06-30 0001589150 2021-04-01 2021-06-30 0001589150 2020-10-01 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150 us-gaap:CommonStockMember 2020-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150 us-gaap:RetainedEarningsMember 2020-09-30 0001589150 RGBP:ContributedCapitalMember 2020-09-30 0001589150 2020-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-12-31 0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-03-31 0001589150 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-09-30 0001589150 us-gaap:CommonStockMember 2021-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001589150 us-gaap:RetainedEarningsMember 2021-09-30 0001589150 RGBP:ContributedCapitalMember 2021-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-12-31 0001589150 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-03-31 0001589150 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01 2020-12-31 0001589150 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-01-01 2021-03-31 0001589150 2021-01-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-04-01 2021-06-30 0001589150 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-04-01 2021-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001589150 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001589150 RGBP:ContributedCapitalMember 2021-04-01 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-10-01 2021-12-31 0001589150 2021-10-01 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-01-01 2022-03-31 0001589150 2022-01-01 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-04-01 2022-06-30 0001589150 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-04-01 2022-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001589150 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001589150 RGBP:ContributedCapitalMember 2022-04-01 2022-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-06-30 0001589150 us-gaap:CommonStockMember 2021-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001589150 us-gaap:RetainedEarningsMember 2021-06-30 0001589150 RGBP:ContributedCapitalMember 2021-06-30 0001589150 2021-06-30 0001589150 RGBP:PreferredStockSeriesAMember 2022-06-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-06-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-06-30 0001589150 us-gaap:CommonStockMember 2022-06-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-06-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001589150 us-gaap:RetainedEarningsMember 2022-06-30 0001589150 RGBP:ContributedCapitalMember 2022-06-30 0001589150 srt:MinimumMember 2021-10-01 2022-06-30 0001589150 srt:MaximumMember 2021-10-01 2022-06-30 0001589150 2021-04-01 2022-06-30 0001589150 RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 2012-04-24 2022-06-30 0001589150 RGBP:DavidKoosMember 2022-06-30 0001589150 RGBP:DavidKoosMember 2022-06-30 0001589150 RGBP:DavidKoosMember 2021-10-01 2022-06-30 0001589150 RGBP:March82016Member 2022-06-30 0001589150 RGBP:April62016Member 2022-06-30 0001589150 RGBP:April62016Member 2022-06-20 0001589150 RGBP:October312016Member 2022-06-30 0001589150 RGBP:October3120161Member 2022-06-30 0001589150 RGBP:October3120162Member 2022-06-30 0001589150 RGBP:October3120162Member 2021-06-30 0001589150 RGBP:March132017Member 2022-06-30 0001589150 RGBP:March132017Member 2021-10-01 2022-06-30 0001589150 RGBP:March312017Member 2022-06-30 0001589150 RGBP:March3120171Member 2022-06-30 0001589150 RGBP:March3120171Member 2021-10-01 2022-06-30 0001589150 RGBP:April192017Member 2022-06-30 0001589150 RGBP:May52017Member 2022-06-30 0001589150 RGBP:May52017Member 2021-10-01 2022-06-30 0001589150 RGBP:June262017Member 2022-06-30 0001589150 RGBP:June262017Member 2021-10-01 2022-06-30 0001589150 RGBP:Sept252017Member 2022-06-30 0001589150 RGBP:Sept252017Member 2021-10-01 2022-06-30 0001589150 RGBP:Oct0317Member 2022-06-30 0001589150 RGBP:Oct0317Member 2021-10-01 2022-06-30 0001589150 RGBP:Oct1617Member 2022-06-30 0001589150 RGBP:Oct1617Member 2021-10-01 2022-06-30 0001589150 RGBP:Nov0117Member 2022-06-30 0001589150 RGBP:Nov0117Member 2021-10-01 2022-06-30 0001589150 RGBP:Nov0120172Member 2022-06-30 0001589150 RGBP:Nov0120172Member 2021-10-01 2022-06-30 0001589150 RGBP:Dec2017Member 2022-06-30 0001589150 RGBP:Dec2017Member 2021-10-01 2022-06-30 0001589150 RGBP:Feb2818Member 2022-06-30 0001589150 RGBP:Feb2818Member 2021-10-01 2022-06-30 0001589150 RGBP:July112018Member 2022-06-30 0001589150 RGBP:July112018Member 2021-10-01 2022-06-30 0001589150 RGBP:September302018Member 2022-06-30 0001589150 RGBP:September302018Member 2021-10-01 2022-06-30 0001589150 RGBP:July192019Member 2022-06-30 0001589150 RGBP:September172021Member 2022-06-30 0001589150 RGBP:September172021Member 2021-10-01 2022-06-30 0001589150 RGBP:March172022Member 2022-06-30 0001589150 RGBP:ZanderTherapeuticsMember 2019-05-30 2019-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2019-11-01 2019-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-06-30 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2022-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-04-01 2021-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-07-01 2021-09-30 0001589150 us-gaap:CommonStockMember 2022-06-30 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2022-06-30 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-05 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-08 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-05-01 2022-05-16 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-06-01 2022-06-09 0001589150 RGBP:AsOriginallyPresentedMember 2021-04-01 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2021-04-01 2021-06-30 0001589150 RGBP:AsRestatedMember 2021-04-01 2021-06-30 0001589150 RGBP:AsOriginallyPresentedMember 2020-10-01 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2020-10-01 2021-06-30 0001589150 RGBP:AsRestatedMember 2020-10-01 2021-06-30 0001589150 RGBP:AsOriginallyPresentedMember 2021-06-30 0001589150 srt:RestatementAdjustmentMember 2021-06-30 0001589150 RGBP:AsRestatedMember 2021-06-30 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-07-15 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-07-01 2022-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended June 30, 2022

 

 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from

 

 Commission File No. 333-191725

 

 REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

 

619 722-5505

(Issuer’s telephone number)

 

None

(Former name, address and fiscal year, if changed since last report)

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐  No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐  Large accelerated filer ☐  Accelerated filer
☐  Non-accelerated filer ☒  Smaller reporting company
  ☐ Emerging Growth Company 

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of July 17, 2022 Regen Biopharma, Inc. had 4,970,002,832  common shares outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.

As of July 17, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

 1 

 

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

           
REGEN BIOPHARMA , INC.      
CONDENSED CONSOLIDATED BALANCE SHEETS      
       
   As of June 30, 2022
(unaudited)		  As of September 30, 2021
ASSETS      
CURRENT ASSETS          
Cash  $110,993   $727,162 
Accounts Receivable, Related Party   295,466    213,192 
Note Receivable, Related Party   5,396    5,396 
Accrued Interest Receivable   629    230 
Prepaid Expenses   27,801    48,144 
     Total Current Assets   440,286    994,124 
           
OTHER ASSETS          
Investment Securities   26,828    198,006 
Investment Securities, Related Party   222,580    19,969 
Total Other Assets   249,408    217,975 
TOTAL ASSETS  $689,693   $1,212,099 
LIABILITIES AND STOCKHOLDERS' EQUITY          
Current Liabilities:          
Accounts payable   28,799    91,498 
Notes Payable   227    1,429,179 
Accrued payroll taxes   4,241    4,241 
Accrued Interest   691,985    954,861 
Accrued Rent        0 
Accrued Payroll   1,266,679    1,266,679 
Other Accrued Expenses   41,423    41,423 
Bank Overdraft   1,000    1,000 
Due to Investor   20,000    20,000 
Unearned Income   1,749,930    1,843,806 
Derivative Liability   3,654,003    6,892,477 
Convertible Notes Payable Less  unamortized discount   1,571,090    2,131,311 
Convertible Notes Payable, Related Parties Less  unamortized discount   10,000    21,500 
Total Current Liabilities   9,039,377    14,697,976 
Long Term Liabilities:          
Convertible Notes Payable, Related Parties Less  unamortized discount        0 
Total Long Term Liabilities          
Total Liabilities   9,039,377    14,697,976 
STOCKHOLDERS' EQUITY (DEFICIT)          
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,920,002,832 issued and outstanding as of June 30,2022 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.   491,999    435,054 
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of June 30,2022  and September 30,2021 respectively          
Series A Preferred; 300,000,000 authorized as of September 30,2021 and 540,000,000 authorized as of June 30, 2022 439,293,406 and 431,998,817 outstanding as of  June 30,2022 and September 30, 2021 respectively   43,929    43,200 
Series AA Preferred; $0.0001 par value 600,000 authorized and 50,000 and 50,000   outstanding as of June 30,2022 and September 30,2021 respectively   5    5 
Series M Preferred; $0.0001 par value 300,000,000 authorized and  44,000,000 outstanding as of September 30,2021 and 60,000,000 authorized and 44,000,000 outstanding as of June 30, 2022   4,400    4,400 
Series NC Preferred; $0.0001 par value 20,000  authorized and 10  outstanding as of September 30, 2021 and June 30,2022 respectively   1    1 
Additional Paid in capital   11,200,998    8,644,037 
Contributed Capital   736,326    736,326 
Retained Earnings (Deficit)   (20,827,342)   (23,348,900)
Total Stockholders' Equity (Deficit)   (8,349,684)   (13,485,877)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)  $689,693   $1,212,099 

The Accompanying Notes are an Integral Part of These Financial Statements

 2 

 

 

                     
REGEN BIOPHARMA , INC.            
CONDENSED CONSOLIDATED  STATEMENTS OF OPERATIONS            
( Unaudited)            
             
    Quarter Ended June 30, 2022    Quarter Ended June 30, 2021 (as restated)    Nine Months Ended June 30, 2022    Nine Months Ended June 30, 2021 (as restated) 
REVENUES                    
Revenues  $31,292   $29,206   $93,877   $29,206 
Revenues, Related Party   27,425    27,425    82,274    82,274 
TOTAL REVENUES   58,717    56,631    176,151    111,480 
                     
COST AND EXPENSES                    
Research and Development   31,061    14,254    93,869    15,893 
Research and Development, Related Party   0    0    117,250    0 
General and Administrative   6,866    24,157    18,879    108,821 
Consulting and Professional Fees   64,700    50,711    152,979    50,711 
Rent   15,000    10,000    35,000    10,000 
Total Costs and Expenses   117,627    99,122    417,977    185,425 
                     
OPERATING INCOME (LOSS)  $(58,910)  $(42,491)  $(241,827)  $(73,945)
                     
OTHER INCOME & (EXPENSES)                    
Interest Income   133    96    399    96 
Interest Expense   (30,399)   (59,569)   (107,970)   (198,029)
Interest Expense attributable to Amortrization of Discount   (22,203)   (414)   (66,631)   (47,063)
Penalties   0    0    (300,000)   0 
Unrealized Gain ( Loss) on sale of Investment Securities   161,729    (308,550)   31,433    (308,550)
Gain(Loss) on sale of Investment Securities        (206,900)        (206,900)
Gain (Loss) on derecognition of Accounts Payable   0    0    62,700    0 
Derivative Income (Expense)   66,907,817    (6,871,286)   3,238,473    (4,546,175)
Gain (Loss) on  Extinguishment Convertible Debt   0    0    (95,019)   0 
TOTAL OTHER INCOME (EXPENSE)   67,017,077    (7,446,623)   2,763,384    (5,306,621)
                     
NET INCOME (LOSS)  $66,958,166   $(7,489,114)  $2,521,557   $(5,380,566)
NET INCOME (LOSS) attributable to common shareholders  $60,931,932   $(7,489,115)  $2,294,618   $(5,380,566)
                     
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE   0.01274   $(0.0021)  $0.0005   $(0.002)
                     
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING   4,783,780,610    3,573,338,986    4794127177    2608298343 

The Accompanying Notes are an Integral Part of These Financial Statements

 3 

 

 

                                                                          
  REGEN BIOPHARMA , INC.
  Condensed Consolidated Statement of Shareholder's Deficit
  (Unaudited)
  Nine Months Ended June 30, 2021 (as restated)
                                          
        Series A Preferred  Series AA Preferred  Series NC Preferred  Common  Series M Preferred         
        Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Shares  Amount  Additional Paid-in Capital  Retained Earnings  Contributed Capital  Total
Balance September 30, 2020    Balance September 30, 2020   381,768,689   $38,177    50,000    5    —    —    1,605,000,246   $160,498    44,000,000   $4,400   $8,313,876   $(16,583,666)  $731,711   $(7,334,998)
Shares issued for Debt 10/28/2020  Shares issued for Debt                                 57,726,183    5,773              (2,021)            3,752
Shares Issued For Interest 10/28/2020  Shares Issued For Interest                                 22,339,663    2,234              (782)            1,452
Shares issued for Debt 11/6/2020  Shares issued for Debt                                 60,007,919    6,001              (2,101)            3,900
Shares Issued For Interest 11/6/2020  Shares Issued For Interest                                 23,926,234    2,393              (838)            1,555
Shares issued for Debt 12/11/2020  Shares issued for Debt                                 60,834,498    6,083              1,217             7,300
Shares Issued For Interest 12/11/2020  Shares Issued For Interest                                 26,185,501    2,619              523             3,142
Shares issued for Debt 12/16/2020  Shares issued for Debt                                 3,300,000    330              99             429
Shares Issued For Interest 12/16/2020  Shares Issued For Interest                                 1,819,077    182              54             236
Shares issued for Fees 12/16/2020  Shares issued for Fees                                 1,228,077    123              36             159
Shares issued for Debt 12/16/2020  Shares issued for Debt                                 62,003,571    6,200              (2,170)            4,030
Shares Issued For Interest 12/16/2020  Shares Issued For Interest                                 26,155,352    2,616              (916)            1,700
Shares issued for Debt 12/17/2020  Shares issued for Debt                                 68,333,539    6,833              1,367             8,200
Shares Issued For Interest 12/17/2020  Shares Issued For Interest                                 14,883,378    1,488              212             1,700
Shares issued for Debt 12/17/2020  Shares issued for Debt   20,000,437    2,000                                            11,000             13,000
Shares Issued For Interest 12/17/2020  Shares Issued For Interest   12,378,732    1,238                                            6,808             8,046
Shares issued for Debt 12/23/2020  Shares issued for Debt                                 88,888,889    8,889              7,111             16,000
Shares Issued For Interest 12/23/2020  Shares Issued For Interest                                 19,555,555    1,956              1,294             3,250
Shares issued for Debt 12/31/2020  Shares issued for Debt                                 82,004,603    8,200              (2,870)            5,330
Shares Issued For Interest 12/31/2020  Shares Issued For Interest                                 35,832,781    3,583              (1,254)            2,329
Additions to Contributed Capital Quarter ended 12/31/2020    Additions to Contributed Capital Quarter ended 12/31/2020                                                               1,865   1,865
Net Loss Quarter Ended December 31,2020    Net Loss Quarter Ended December 31,2020        —         —         —                   —         1,666,367        1,666,367
Balance December 31, 2020    Balance December 31, 2020   414,147,858   $41,415    50,000    5    —    —    2,260,025,066   $226,001    44,000,000   $4,400   $8,330,646   $(14,917,299)  $733,576   $(5,581,256)
shares issued for debt 1/28/2021  shares issued for debt                                 85,900,000    8,590              (3,436)            5,154
shares issued for interest 2/23/2021  shares issued for interest                                 88,000,000    8,800              (4,400)            4,400
shares issued for debt 2/24/2021  shares issued for debt                                 71,430,421    7,143              22,857             30,000
shares issued for interest 2/24/2021  shares issued for interest                                 11,328,865    1,133              3,625             4,758
shares issued for debt 3/2/2021  shares issued for debt                                 80,928,505    8,093              (2,833)            5,260
shares issued for interest 3/2/2021  shares issued for interest                                 38,341,033    3,834              (1,342)            2,492
 shares issued for debt 3/9/2021  shares issued for debt                                 67,175,355    6,718              (3,361)            3,357
shares issued for interest 3/9/2021  shares issued for interest                                 8,824,645    882              (441)            441
shares issued for debt 3/12/2021  shares issued for debt                                 16,666,667    1,667              (667)            1,000
shares issued for interest 3/12/2021  shares issued for interest                                 95,833,333    9,583              (3,833)            5,750
shares issued for debt 3/18/2021  shares issued for debt                                 68,319,520    6,832              (3,417)            3,415
shares issued for interest 3/18/2021  shares issued for interest                                 1,680,480    168              (84)            84
shares issued for debt 3/31/2021  shares issued for debt                                 38,519,260    3,852              (1,927)            1,925
shares issued for interest 3/31/2021  shares issued for interest                                 1,480,740    148              (74)            74
Additions to Contributed Capital Quarter ended 3/31/2021    Additions to Contributed Capital Quarter ended 3/31/2021                                                               250   250
Net Income for the Quarter Ended March 31,2021      Net Income for the Quarter Ended March 31,2021        —         —         —              —    —         442,183        442,183
Balance March 31, 2021    Balance March 31, 2021   414,147,858   $41,415    50,000    5    0    0    2,934,453,890   $293,444    44,000,000   $4,400   $8,331,313   $(14,475,117)  $733,826   $(5,070,713)
Shares issued for Debt 4/12/2021  Shares issued for Debt                                 84,214,968    8,421              (5,310)            3,111
Shares issued for interest 4/12/2021  Shares issued for interest                                 785,032    79              (30)            49
Preferred Shares issued for Services 4/13/2021  Preferred Shares issued for Services                       10000    1                                      1
Shares issued for Debt 4/13/2021  Shares issued for Debt                                 26,389,990    2,639              16,361             19,000
Shares issued for interest 4/13/2021  Shares issued for interest                                 6,578,052    658              4,078             4,736
Shares issued for Debt 4/13/2021  Shares issued for Debt                                 58,502,448    5,850              (2,340)            3,510
Shares issued for interest 4/13/2021  Shares issued for interest                                 25,134,385    2,513              (1,005)            1,508
Shares issued for Debt 4/15/2021`  Shares issued for Debt                                 97,542,355    9,754              (3,414)            6,340
Shares issued for interest 4/15/2021`  Shares issued for interest                                 48,909,645    4,891              (1,712)            3,179
Shares issued for Debt 4/15/2021`  Shares issued for Debt                                 38,145,154    3,815              (1,527)            2,288
Shares issued for interest 4/15/2021`  Shares issued for interest                                 11,336,846    1,134              (454)            680
Shares issued for Debt 4/15/2021`  Shares issued for Debt                                 89,950,579    8,995              (4,757)            4,238
Shares issued for interest 4/15/2021`  Shares issued for interest                                 360,821    36              (19)            17
Shares issued for Debt 4/16/2021`  Shares issued for Debt                                 60,257,055    6,026              40,974             47,000
Shares issued for interest 4/16/2021`  Shares issued for interest                                 10,498,830    1,050              7,139             8,189
Shares issued for Debt 4/21/2021  Shares issued for Debt                                 126,423,649    12,642              (4,987)            7,655
Shares issued for interest 4/21/2021  Shares issued for interest                                 37,390,351    3,739              (1,475)            2,264
Shares issued for Debt 4/28/2021  Shares issued for Debt                                 24,445,152    2,445              19,555             22,000
Shares issued for interest 4/28/2021  Shares issued for interest                                 4,339,015    434              3,471             3,905
Shares issued for Debt 5/3/2021  Shares issued for Debt                                 21,792,903    2,179              (763)            1,416
Shares issued for interest 5/3/2021  Shares issued for interest                                 11,219,652    1,122              (393)            729
Shares issued for Debt 5/5/2021  Shares issued for Debt                                 18,271,120    1,827              (640)            1,187
Shares issued for interest 5/5/2021  Shares issued for interest                                 9,481,896    948              (332)            616
Shares issued for Debt 5/18/2021  Shares issued for Debt                                 33,772,000    3,377              (1,351)            2,026
Contributed Capital Quarter Ended June 30, 2021    Contributed Capital Quarter Ended June 30, 2021                                                               2,500   2,500
Net Loss for the Quarter Ended June 30,2021    Net Loss for the Quarter Ended June 30,2021        —         —         —                   —         (7,489,115)       (7,489,115)
Balance June 30, 2021   Balance June 30, 2021   414,147,858   $41,415    50,000   $5    10,000   $1    3,780,195,788   $378,018    44,000,000   $4,400   $8,392,382   $(21,964,232)  $736,326   $(12,411,685)
Balance September 30, 2021   Balance September 30, 2021   431,998,817   $43,200    50,000   $5    10,000   $1    4,350,554,514   $435,054    44,000,000   $4,400   $8,644,037   $(23,348,900)  $736,326   $(13,485,877)
Shares issued for Debt 10/1/2021  Shares issued for Debt                                 10,000,000    1,000              99,000             100,000
Shares issued for Interest 10/1/2021  Shares issued for Interest                                 2,666,200    267              26,395             26,662
Shares issued for Debt 10/1/2021  Shares issued for Debt                                 10,000,000    1,000              99,000             100,000
Shares issued for Interest 10/1/2021  Shares issued for Interest